Imperial College London
Alternate

ProfessorElioRiboli

Faculty of Medicine, School of Public Health

Chair in Cancer Epidemiology and Prevention
 
 
 
//

Contact

 

e.riboli Website CV

 
 
//

Assistant

 

Ms Julieta Dourado +44 (0)20 7594 3426

 
//

Location

 

152Medical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Anderson:2020:10.1038/s41416-020-01154-3,
author = {Anderson, AS and Renehan, AG and Saxton, JM and Bell, J and Cade, J and Cross, AJ and King, A and Riboli, E and Sniehotta, F and Treweek, S and Martin, RM and Beeken, R and Mitrou, G},
doi = {10.1038/s41416-020-01154-3},
journal = {British Journal of Cancer},
pages = {1049--1056},
title = {Cancer prevention through weight control-where are we in 2020?},
url = {http://dx.doi.org/10.1038/s41416-020-01154-3},
volume = {124},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Growing data from epidemiological studies highlight the association between excess body fat and cancer incidence, but good indicative evidence demonstrates that intentional weight loss, as well as increasing physical activity, offers much promise as a cost-effective approach for reducing the cancer burden. However, clear gaps remain in our understanding of how changes in body fat or levels of physical activity are mechanistically linked to cancer, and the magnitude of their impact on cancer risk. It is important to investigate the causal link between programmes that successfully achieve short-term modest weight loss followed by weight-loss maintenance and cancer incidence. The longer-term impact of weight loss and duration of overweight and obesity on risk reduction also need to be fully considered in trial design. These gaps in knowledge need to be urgently addressed to expedite the development and implementation of future cancer-control strategies. Comprehensive approaches to trial design, Mendelian randomisation studies and data-linkage opportunities offer real possibilities to tackle current research gaps. In this paper, we set out the case for why non-pharmacological weight-management trials are urgently needed to support cancer-risk reduction and help control the growing global burden of cancer.
AU  - Anderson,AS
AU  - Renehan,AG
AU  - Saxton,JM
AU  - Bell,J
AU  - Cade,J
AU  - Cross,AJ
AU  - King,A
AU  - Riboli,E
AU  - Sniehotta,F
AU  - Treweek,S
AU  - Martin,RM
AU  - Beeken,R
AU  - Mitrou,G
DO  - 10.1038/s41416-020-01154-3
EP  - 1056
PY  - 2020///
SN  - 0007-0920
SP  - 1049
TI  - Cancer prevention through weight control-where are we in 2020?
T2  - British Journal of Cancer
UR  - http://dx.doi.org/10.1038/s41416-020-01154-3
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000599063400003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.nature.com/articles/s41416-020-01154-3#Abs1
UR  - http://hdl.handle.net/10044/1/85809
VL  - 124
ER  -
Download